

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/494,096
		Filing Date	January 28, 2000
		First Named Inventor	Gary A. Bannon
		Group Art Unit	1643, 1644
		Examiner Name	HUYNH, P
Attorney Docket Number	HS 102 CIP (2)		

Sheet 1 of 2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ²	Number ⁴	Kind Code ⁵ (if known)				
PAT ↓		WO	95/07933	A1	Allergene, Inc.	03-23-1995		
		WO	97/24139	A1	University of Arkansas	07-10-1997		
		WO	98/43657	A2	Merck Patent GMBH	10-08-1998		
		WO	99/38978	A1	University of Arkansas; Mt. Sinai School of Medicine of the City of New York	08-05-1999		

Examine Signature	<i>Phy N. [Signature]</i>	Date Considered	2/12/02
-------------------	---------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/494,096
		Filing Date	January 28, 2000
		First Named Inventor	Gary A. Bannon
		Group Art Unit	1643 1644
		Examiner Name	HUYNH, P
Sheet 2 of 2	Attorney Docket Number	HS 102 CIP (2)	

RECEIVED

FEB 15 2001

TECH CENTER 1600/2900

FEB 12 2001

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PJK ↓ ✓		FERREIRA, et al., "Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy," <i>FASEB J</i> 12:231-242 (1998).	
		RABJOHN, et al., "Molecular cloning and epitope analysis of the peanut allergen Ara h 3," <i>Journal of Clinical Investigation</i> 103(4):535-541 (1999).	
		TAKAI, et al., "Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy," <i>Nature Biotechnology</i> 15:754-58 (1997).	
		TAKASHI, et al., "Engineering of hypoallergenic mutants of the <i>Brassica</i> pollen allergen, Bra r 1, for immunotherapy," <i>FEBS Letters</i> 434:255-260 (1998).	

Examiner's Signature	<i>Phy N. HS</i>	Date Considered	2/12/02
----------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/494,096
		Filing Date	January 28, 2000
		First Named Inventor	Gary A. Bannon
		Group Art Unit	1643
		Examiner Name	
Sheet	2	of	10
		Attorney Docket Number	HS 102 CIP (2)

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		AAS, et al., "Physico-chemical properties and specific activity of a purified allergen (codfish)," <i>Dev. Biol. Stand.</i> 29:90-98 (1975).	
		Abstracts 585-592, <i>J. Allergy Clin. Immunol.</i> 97, January 1996.	
		Abstracts 765-772, <i>J. Allergy Clin. Immunol.</i> 95, January 1995.	
		*ALENIUS, et al., "The main IgE-binding epitope of a major latex allergen, prohevein, is present in its N-terminal 43-amino acid fragment, hevein," <i>J. Immunol.</i> 156(4):1618-1625 (1996).	
		*ALENIUS, et al., "Prohevein from the rubber tree (<i>Hevea brasiliensis</i>) is a major latex allergen," <i>Clin. Exp. Allergy</i> 25(7):659-665 (1995).	
		BALL, et al., "A major continuous allergenic epitope of bovine beta-lactoglobulin recognized by human IgE binding," <i>Clin. Exp. Allergy</i> 24:758-764 (1994).	
		BARNETT, et al., "Partial Characterization of an allergenic glycoproteins from peanut," <i>Biochimica et Biophysica Acta</i> 882:97-105 (1986).	
		BEVIER, "Flea Allergy Dermatitis Testing Breakthrough," <i>Canine Practice</i> 22(2-3):49-50 (1997).	
		BOCK, "Natural history of severe reactions to foods in young children," <i>J. Pediatr.</i> 107:676-680 (1985).	
		BOULET, et al., "Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response," <i>Am J Respir Crit Care Med</i> 155:1835-1840 (1997).	

Examiner's Signature		Date Considered	2/12/02
----------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/494,096		
		Filing Date	January 28, 2000		
		First Named Inventor	Gary A. Bannon		
		Group Art Unit	1643		
		Examiner Name			
Sheet	3	of	10	Attorney Docket Number	HS 102 CIP (2)

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BSAC Working Party, "Position paper on allergen immunotherapy," <i>Clin Exp Allergy</i> 23:1-44 (1993).	
		BURKS, "Allergenicity of peanut and soybean extracts altered by chemical or thermal denaturation in patients with atopic dermatitis and positive food challenges," <i>J Allergy Clin Immunol</i> 90(6 pt 1):889-97 (1992).	
		BURKS, et al., "Atopic dermatitis: clinical relevance of food hypersensitivity reactions," <i>J. Pediatr.</i> 113:447-451 (1988).	
		BURKS, et al., "Mapping and mutational analysis of the IgE-binding epitopes on Ara h 1, a legume vicilin protein and a major allergen in peanut hypersensitivity," <i>Eur. J. Biochem.</i> 245:334-339 (1997).	
		BURKS, et al., "Recombinant peanut allergen Ara h I expression and IgE binding in patients with peanut hypersensitivity," <i>J. Clinical Invest.</i> 96:1715-1721 (1995).	
		BURKS, et al., "Allergens, IgE, mediators, inflammatory mechanisms. Epitope specificity and immunoaffinity purification of the major peanut allergen, Ara h I," <i>J Allergy Clin Immunol.</i> 93(4):743-50 (1994).	
		BURKS, et al., "Epitope specificity of the major peanut allergen, Ara h II," <i>J Allergy Clin Immunol.</i> 95(2):607-11. (1995).	
		BURKS, et al., "Identification and characterization of a second major peanut allergen, Ara h II, with use of the sera of patients with atopic dermatitis and positive peanut challenge," <i>J Allergy Clin Immunol.</i> 90(6 Pt 1):962-9 (1992).	
		BURKS, et al., "Identification of a second major peanut allergen in patients with atopic dermatitis and peanut hypersensitivity," <i>J. Allergy Clin. Immunol.</i> 87:211 (1991).	
		BURKS, et al., "Production of murine monoclonal (mAb) antibodies to Ara H1, A 63.5 kD Allergen in peanuts," <i>J. Allergy Clin. Immunol.</i> 87:210 (1991).	

Examiner's Signature		Date Considered	2/12/02
-------------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/494,096		
		Filing Date	January 28, 2000		
		First Named Inventor	Gary A. Bannon		
		Group Art Unit	1643		
		Examiner Name			
Sheet	4	of	10	Attorney Docket Number	HS 102 CIP (2)

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	7 ²
		BURKS, et al., "Identification of a major peanut allergen Ara h 1, in patients with atopic dermatitis and positive peanut challenge," <i>J. Allergy Clin. Immunol.</i> 88:172-179 (1991).	
		BURKS, et al., "Identification of peanut agglutinin and soybean trypsin inhibitor as minor legume allergens," <i>Int Arch Allergy Immunol.</i> 105(2):143-9 (1994).	
		BURKS, et al., "Isolation, identification, and characterization of clones encoding antigens responsible for peanut hypersensitivity," <i>Int Arch Allergy Immunol.</i> 107(1-3):248-50 (1995).	
		CHAPMAN, "Monoclonal antibodies as structural probes for mite, cat, and cockroach allergens," <i>Adv. Biosci.</i> 74 (1989).	
		*CHEN, et al., "Isolation and identification of hevein as a major IgE-binding polypeptide in Hevea latex," <i>J. Allergy Clin. Immunol.</i> 99(3):402-409 (1997).	
		COCKRELL, et al., "Monoclonal antibody enzyme-linked immunosorbent assay (ELISA) for Ara H 1. A major peanut allergen," <i>J. Aller. Clin. Immunol.</i> 89:Abstract 613 (1992).	
		COLMAN, "Production of proteins in the milk of transgenic livestock: problems, solutions, and successes," <i>Am. J. Clin. Nutr.</i> 63(4):639S-6455S (1996).	
		COLMAN, A " Production of therapeutic proteins in the milk of transgenic livestock" <i>Biochem. Soc. Symp.</i> 63:141-147 (1998).	
		*COOKE & SAMPSON, "Allergenic properties of ovomucoid in man," <i>J. Immunol.</i> 159(4):2026-32 (1997).	
		DAY, "Genetic Modification of Proteins in Food," <i>Critical Reviews in Food Science and Nutrition</i> 36(S):S49-S67 (1996).	

Examiner's Signature		Date Considered	2/12/02
----------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/494,096
		Filing Date	January 28, 2000
		First Named Inventor	Gary A. Bannon
		Group Art Unit	1643
		Examiner Name	
Sheet 5 of 10	Attorney Docket Number	HS 102 CIP (2)	

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		DEJONG, et al., "Food allergen (peanut)-specific TH2 clones generated from the peripheral blood of a patient with peanut allergy," <i>J Allergy Clin Immunol.</i> 98(1):73-81 (1996).	
		*DEMOLY, et al., "Anti-IgE therapy for asthma," <i>American J Resp. Crit. Care Med.</i> 155:1825-1827 (1997).	
		Directions for use, Pharmacia Diagnostics AB, Uppsala, Sweden 1985 (Revised 1988).	
		*EICHLER & HOUGHTEN, "Generation and utilization of synthetic combinatorial libraries," <i>Mol. Med. Today</i> 1(4):174-80 (1995).	
		ELSAYED, et al., "Synthetic allergenic epitopes from the amino-terminal regions of the major allergens of hazel and birch pollen," <i>Int. Arch. Allergy Appl. Immunol.</i> 89:410-415 (1989).	
		ESPANION, "Methods of production and perspectives for use of transgenic domestic animals," <i>DTW Dtsch Tierarztl Wochenschr.</i> 103(8-9):320-8 (1996).	
		FAHY, et al., "The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects," <i>American J Respir Crit Care Med</i> 155:1828-1834 (1997).	
		FIELDS, et al., "Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids," <i>Int J Pept Protein Res.</i> 35(3):161-214 (1990).	
		FOSTER, "Allergy Testing for Skin disease in the Cat <i>In Vivo</i> vs <i>In Vitro</i> tests," <i>Veterinary Immunology</i> 4(3):111-115 (1993).	
		*FUCHS, et al., "Ingredients for fat replacement," <i>Food Tech.</i> 51:82-87 (1997).	

Examiner's Signature		Date Considered	2/12/02
----------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	09/494,096
				Filing Date	January 28, 2000
				First Named Inventor	Gary A. Bannon
				Group Art Unit	1643
				Examiner Name	
				Attorney Docket Number	HS 102 CIP (2)
Sheet	6	of	10		

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		GREENE, "Characterization of allergens of the cat flea, <i>Ctenocephalides felis</i> : detection and frequency of IgE antibodies in canine sera," <i>Parasit Immunology</i> 15:69-74 (1993).	
		HALLIWELL, "Aspects of the Immunopathogenesis of Flea Allergy Dermatitis in Dogs," <i>Veterinary Immunology and Immunopathology</i> 17:483-494 (1987).	
		HALLIWELL, "IgE and IgG Antibodies to flea Antigen in Differing Dog Populations," <i>Veterinary Immunology and Immunopathology</i> 8:215-223 (1985).	
		HEFLE, et al., "Isolation of peanut allergens using monoclonal antibodies," <i>J. Allergy and Clinical Immunology</i> 87:Abstract 209 (1991).	
		HERIAN, et al. "Identification of soybean allergens by immunoblotting with sera from soy-allergic adults," <i>Int. Arch. Allergy Appl. Immunol.</i> 92:193-198 (1990).	
		HSU et al., "Inhibition of specific IgE response in vivo by allergen-gene transfer," <i>Int Immunol</i> 8:1405-1411 (1996).	
		KAMINOGAWA, "Food allergy, oral tolerance and immunomodulation--their molecular and cellular mechanisms," <i>Biosci. Biotech. Biochem.</i> 60:1749-1756 (1996).	
		KEATING, et al., "Immunoassay of peanut allergens in food-processing material and finished foods," <i>J. Allergy Clin. Immunol.</i> 86:41-44 (1990).	
		*KIELISZEWSKI, et al., "Potato lectin: a modular protein sharing sequence similarities with the extensin family, the hevein lectin family, and snake venom disintegrins (platelet aggregation inhibitors)," <i>Plant J.</i> 5(6):849-861 (1994).	
		KOHLER, et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> 256:495-497 (1975).	

Examiner's Signature		Date Considered	2/12/02
----------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/494,096
		Filing Date	January 28, 2000
		First Named Inventor	Gary A. Bannon
		Group Art Unit	1643
		Examiner Name	
Sheet	7	of	10
		Attorney Docket Number	HS 102 CIP (2)

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		*KRIEG, et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," <i>Nature</i> 374(6522):546-9 (1995).	
		MCKEON, "IgG and IgE Antibodies Against Antigens of the Cat Flea, <i>Ctenocephalides Felis Felis</i> in Sera of Allergic and Non-allergic Dogs," <i>Int. J. Parasitology</i> 24(2):259-263 (1994).	
		MONERET-VAUTRIN, "Modifications of allergenicity linked to food technologies," <i>Allerg Immunol</i> 30(1):9-13 (1998).	
		NELSON, et al., "Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract," <i>J. Allergy Clin. Immunol.</i> 99:744-751 (1997).	
		*NOON, "Prophylactic inoculation against hay fever," <i>Lancet</i> 1:1572-73 (1911).	
		NORMAN, et al., "Multicenter study of several doses of ALLER-VAX® Cat peptides in the treatment of cat allergy," <i>Journal of Allergy and Clinical Immunology</i> 99:S127 (1997).	
		OPPENHEIMER, et al., "Treatment of peanut allergy with rush immunotherapy," <i>J Allergy Clin Immunol.</i> 90:256-62 (1992).	
		Phadebas Rast Radioimmunoassay Reagents for 100 or 300 Tubes, Pharmacia Diagnostics AB, Uppsala Sweden 1985, Revised January 1988.	
		*PISETSKY, "Immune activation by bacterial DNA: a new genetic code," <i>Immunity</i> 5(4):303-10 (1996).	
		POLLART, et al., "Identification, quantitation, and purification of cockroach allergens using monoclonal antibodies," <i>J. Allergy Clin. Immunol.</i> 87:511-521 (1991).	

Examiner's Signature		Date Considered	2/12/02
----------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/494,096
		Filing Date	January 28, 2000
		First Named Inventor	Gary A. Bannon
		Group Art Unit	1643
		Examiner Name	
Sheet 8 of 10	Attorney Docket Number	HS 102 CIP (2)	

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		*POSCH, et al., "Characterization and identification of latex allergens by two-dimensional electrophoresis and protein microsequencing," <i>J. Allergy Clin. Immunol</i> 99(3):385-395 (1997).	
		PUCHEU-HASTON, "Allergenic cross-reactivities in flea-reactive canine serum samples," <i>AJVR</i> 57(7):1000-1005 (1996).	
		RAZ, et al., "Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses," <i>Proc Nat Acad Sci USA</i> 91:9519-9523 (1994).	
		ROLFSEN, "Detection of specific IgE antibodies towards cat flea (<i>Ctenocephalides felis felis</i>) in patients with suspected cat allergy," <i>Allergy</i> 42:177-181 (1987).	
		ROONEY, et al., "Antiparallel, intramolecular triplex DNA stimulates homologous recombination in human cells," <i>Proc. Natl. Acad. Sci. USA</i> 92: 2141-2144 (1995).	
		SAMPSON, et al., "Fatal and near-fatal anaphylactic reactions to food in children and adolescents," <i>N Engl J Med</i> 327:380-384 (1992).	
		SAMPSON, "Food allergy and the role of immunotherapy," <i>J Allergy Clin. Immun.</i> 90:151-52 (1992).	
		SAMPSON, et al., "Mechanisms of food allergy," <i>Annu. Rev. Nutr.</i> 16:161-77 (1996).	
		SCHEMMER, "Efficacy of Alum-Precipitated Flea Antigen for Hyposensitization of Flea-Allergic Dogs," <i>Seminars in Veterinary Medicine and Surgery (Small Animal)</i> 2(3):195-198 (1987).	
		SEVIER, et al., "Monoclonal Antibodies in clinical immunology," <i>Clin. Chem.</i> 27:11, 1797-1806 (1981).	

Examiner's Signature		Date Considered	2/12/02
----------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/494,096
		Filing Date	January 28, 2000
		First Named Inventor	Gary A. Bannon
		Group Art Unit	1643
		Examiner Name	
Sheet 9 of 10	Attorney Docket Number	HS 102 CIP (2)	

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SHANTI, et al., "Identification of tropomyosin as the major shrimp allergen and characterization of its IgE-binding epitopes," <i>J. Immunol.</i> 151:5354-5363 (1993).	
		SHIN, et al., "Biochemical and structural analysis of the IgE binding sites on Ara h1, an abundant and highly allergenic peanut protein," <i>J Biol Chem.</i> 273(22):13753-9 (1998).	
		STANLEY, et al., "Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2," <i>Arch. Biochem. Biophys.</i> 342:244-253 (1997).	
		STANLEY, et al., "Peanut hypersensitivity. IgE binding characteristics of a recombinant Ara h 1 protein," <i>Adv Exp Med Biol.</i> 409:213-6 (1996).	
		STEINBERGER, et al., "Construction of a combinatorial IgE library from an allergic patient. Isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, Phl p 5," <i>J. Biol. Chem.</i> 271:10967-10982 (1996).	
		SZOSTAK, "In vitro genetics," <i>TIBS</i> 19:89 (1992).	
		THOMAS, et al., "Purification of membrane proteins," <i>Meth. Enzymol.</i> 182:499-520 (1990).	
		TWARDOSZ, "Molecular Characterization, Expression in Escherichia coli, and Epitope Analysis of a Two EF-Hand Calcium-Binding Birch Pollen Allergen, Bet v 4," <i>Biochem. Biophys. Res. Commun.</i> 239:197-204 (1997).	
		VOLLER, et al., "Enzyme-linked immunosorbent assay," <i>Manual of Clinical Laboratory Immunology</i> , (Rose, ed.), Chap. 17, Third Edition, pp. 99-109, 1986.	
		VRTALA, "High Level Expression in Escherichia coli and Purification of Recombinant Plant Profilins: Comparison of IgE Binding Capacity and Allergenic Activity," <i>Biochem. Biophys. Res. Comm.</i> 226:42-50 (1996).	

Examiner's Signature	<i>[Signature]</i>	Date Considered	2/12/02
----------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/494,096
				Filing Date	January 28, 2000
				First Named Inventor	Gary A. Bannon
				Group Art Unit	1643
				Examiner Name	
Sheet	10	of	10	Attorney Docket Number	HS 102 CIP (2)

[illegible]

Examiner's Signature		Date Considered	2/17/02
----------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**